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INTRODUCTION 
 
Cytochrome P450 enzymes (CYPs) are responsible for the oxidative 
metabolism of a diverse range of xenobiotics including therapeutic drugs, carcinogens, 
toxicants and endogenous compounds, such as steroid hormones and bile acids [1, 2]. In 
particular, CYP3A, the most abundant CYP subfamily expressed in both liver and 
intestine, plays central roles in the first-pass metabolism of more than half of currently 
available therapeutic drugs [3]. In addition, CYP3A enzymes are susceptible to 
induction and inhibition by a variety of drugs. Therefore, it has been considered that 
CYP3A enzymes are the significant determinants of drug bioavailability and drug-drug 
interaction (DDI). This is of particular concern in the development of new drugs, 
because many drugs are used in combination therapies leading to serious DDI. Some 
drugs (e.g., mibefradil and terfenadine) have been withdrawn from the markets, because 
of the potential of fatal adverse reaction from DDI mediated by CYP3A [4]. 
Given the importance of CYP3A, in vitro studies using human liver 
microsomes, human hepatocytes, cDNA-expressed enzymes, cell-based cultures and 
reporter vector systems have been performed in the preclinical development stage to 
examine whether the drug candidates are substrates, inhibitors and/or inducers of 
CYP3A [5]. However, they cannot be appropriately indicative of the in vivo situation. 
The experimental animals especially rodents have been generally used as in vivo animal 
models to predict pharmacokinetics in humans. However, the researchers have often 
suffered from the inaccuracy of human pharmacokinetics prediction using experimental 
animals, because of the species differences in substrate specificities [6]. 
DDI arising from irreversible inhibition of CYP3A via mechanism-based 
inactivation (MBI) often causes serious adverse drug reaction [4]. Therefore, attention 
has been paid to the prediction of MBI arising from CYP3A in the development of new 
drug entities to avoid dangerous DDI. Compared to the prediction of human 
pharmacokinetics using animals, less effort has been direct toward predicting clinical 
DDI using in vivo animal models because of substantial species differences in inhibitor 
sensitivities of CYP3A [7,8]. The development of the reliable in vivo models for 
prediction of clinical DDI potential especially induced by MBI of CYP3A is still 
challenging in the research of new drugs. 
In an approach to overcome problems of the species differences in CYP3A 
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enzymes between humans and experimental animals, CYP3A-transgenic mouse lines 
carrying the specific CYP3A isoform have been constructed [9-13]. However, it has not 
been succeeded in the construction of mouse line that carries the entire human CYP3A 
cluster, because of the limitation of conventional cloning techniques in transferring a 
large size of genes. Recently, the chromosome cloning techniques using human artificial 
chromosome (HAC) vector system have been developed [14-16]. The advantages of 
HAC vector system over the conventional techniques using cloned transgenes are as 
follows: (1) whole genomic sequences including all the introns and essential regulatory 
elements can be used as transgenes, which results in the correctly controlled expression 
of transgenes in vivo; (2) very large genes and gene clusters, which cannot be cloned as 
contiguous DNA fragments by the conventional cloning techniques, can be introduced; 
(3) HAC vectors are maintained as a single copy chromosome in the host cells, which 
can prevent gene silencing caused by multiple copy insertion of transgenes; (4) HAC 
vectors are stably maintained and transmittable to the mouse germlines. Using the 
developed HAC vector system [14,16], Oshimura and his collaborators have succeeded 
in generation of CYP3As-humanized mice designed as CYP3A-HAC mice. The 
CYP3A-HAC mice carry all of human CYP3A genes in CYP3A cluster (CYP3A4, 
CYP3A5, CYP3A7 and CYP3A43) and their essential regulatory regions in mouse Cyp3a 
knockout background. The CYP3A-HAC mouse line may be more reliable in vivo 
model than wild-type (WT) animals and available CYP3A-transgenic mouse lines for 
prediction of human pharmacokinetics including clinical DDI potential mediated by 
CYP3A. 
In Chapter I, we performed functional characterization of CYP3A-HAC mice 
by examining expression and metabolic function of CYP3A enzymes using triazolam 
(TRZ) as a specific CYP3A probe. In Chapter II, to assess whether CYP3A-HAC mice 
is useful for prediction of clinical DDI induced by CYP3A-mediated MBI, we 
examined species differences in MBI of CYP3A by CYP3A inhibitors between humans 
and rodents, and performed in vitro studies on MBI effects of the representative CYP3A 
inhibitors on CYP3A activity in the liver and intestine of CYP3A-HAC mice. 
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I-I: Introduction 
The human CYP3A family consists of four members (CYP3A4, CYP3A5, 
CYP3A7 and CYP3A43), whereas mice have eight complete Cyp3a genes (Cyp3a11, 
Cyp3a13, Cyp3a16, Cyp3a25, Cyp3a41, Cyp3a44, Cyp3a57 and Cyp3a59) and three 
pseudogenes [17]. Using the developed HAC vector system [14], Oshimura and his 
collaborators have recently generated CYP3A-HAC mouse line carrying the entire 
human CYP3A cluster in mouse Cyp3a knockout background. Oshimura and his 
collaborators demonstrated that CYP3A4 and CYP3A5 mRNAs were mainly expressed 
in the liver and intestine of CYP3A-HAC mice, and CYP3A5 mRNA was also 
expressed in the lung, which were consistent with the expression profiles of CYP3A4 
and CYP3A5 in humans [1,18]. Furthermore, CYP3A4 mRNA was mainly expressed in 
the liver of adult CYP3A-HAC mice, whereas CYP3A7 mRNA was dominantly 
expressed in the fatal liver of CYP3A-HAC mice. These developmental expression 
profiles of CYP3A4 and CYP3A7 mRNAs were consistent with the previous reports in 
humans [19,20]. However, it has not been examined whether human CYP3A genes are 
expressed as the functional enzymes in the liver and intestine of CYP3A-HAC mice. 
To characterize CYP3A enzymes expressed in CYP3A-HAC mouse line, it is 
necessary to use a probe specific to CYP3A subfamily in both humans and mice. TRZ 
and midazolam have been widely used as the CYP3A probes both in vitro and in vivo, 
because they are completely excreted through metabolism and are not the substrates of 
P-glycoprotein [21,22]. Although both TRZ and midazolam are specifically metabolized 
by CYP3A in humans, it has been reported that midazolam was less specific to CYP3A 
than TRZ in mice [23]. In addition, it has been reported that the metabolism of 
midazolam was significantly observed in Cyp3a(-/-) mice, but the metabolism of TRZ 
was not [13,24]. Therefore, TRZ would be suitable CYP3A probe for characterization of 
the functional human CYP3A enzymes expressed in CYP3A-HAC mice. 
In this chapter, we aimed to characterize the human CYP3A enzymes 
expressed in CYP3A-HAC mice. We examined the expression and inducibility of 
CYP3A4 mRNA and CYP3A proteins by real-time PCR and Western blot analyses, 
respectively, in the liver and intestine of CYP3A-HAC mice. In addition, we analyzed 
the metabolic function of CYP3A enzymes expressed in the liver and intestine of 
CYP3A-HAC mice by using TRZ as a CYP3A probe and performed the 
 - 7 - 
immunoinhibition assay using anti-human CYP3A4 antibody. The results obtained from 
CYP3A-HAC mice were compared with those of humans and WT mice. 
 
I-II: Materials and Methods 
Chemicals 
TRZ was purchased from Wako Pure Chemicals (Osaka). 1’-Hydroxy TRZ (1’-OH 
TRZ) and 4-hydroxy TRZ (4-OH TRZ) were supplied by Nihon Upjohn Co. (Tokyo). 
Ethoxyresorufin, methoxyresorufin and resorufin were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Other reagents were of analytical or HPLC grade and obtained 
commercially. 
Animals 
WT mice (C57BL/6Cr), Cyp3a-knockout mice (CYP3A-KO) and 
CYP3As-humanized mice in CYP3A-KO background (CYP3A-HAC) used in this study were 
male and 9-18 weeks of age. CYP3A-HAC mice used in this study were interbred for 4-5 
generations. The present study was conducted in accordance with the guidelines for the Care 
and Use of Laboratory Animals, as adopted by the Committee on Animal Research of Tottori 
University and Chiba University. 
PCN treatment 
 Pregnenolone 16α-carbonitrile (PCN; Sigma-Aldrich) was used as a typical CYP3A 
inducer. PCN was dissolved in corn oil (Wako Pure Chemicals) and intraperitoneally 
administered to mice at a dose of 100 mg/kg for 4 days. 
RNA isolation and cDNA synthesis 
Total RNA was isolated from livers and upper part of small intestines by using a 
FastPureTM RNA Kit (Takara, Shiga) according to the manufacturer’s instructions. The cDNA 
was generated with a random hexamer by using a High-Capacity cDNA Reverse Transcription 
Kit (Applied Biosytems, Foster, CA, USA).  
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Quantification of the expression level of CYP3A4 mRNA 
The expression level of CYP3A4 mRNA in liver and intestinal tissues was measured 
by quantitative real-time PCR carried out on an ABI PRISM 7000 (Applied Biosystems) using 
TaqMan Gene Expression Assays specific to CYP3A4 mRNA (FAM/MGB Probe; 
Hs00604506_m1, Applied Biosystems). A PCR reaction mixture of 25 µL contained 12.5 µL of 
2x Taqman Universal PCR Mastermix (Applied Biosystems), 1.25 µL of TaqMan Gene 
Expression Assay for CYP3A4 or mouse GAPDH (VIC/MGB probe, Primer Limited, Applied 
Biosystems) and 1 µL of template cDNA. The amplification consisted of one cycle of 50ºC with 
a 2-min hold, 95ºC with a 10-min hold, followed by 40 cycles of denaturing temperature at 95ºC 
with a 15-sec hold, annealing and extension temperature at 60ºC with a 1-min hold. The 
expression level of CYP3A4 mRNA was normalized with the expression level of mouse 
GAPDH as an endogenous control gene. Data are shown as means ?S.E. of 3-4 mice from 
three independent measurements, each performed in duplicate.  
Liver and intestinal microsomes of humans 
Pooled human liver microsomes prepared from 25-30 donors were purchased from 
BD Gentest (Woburn, MA, USA). Pooled human intestinal microsomes prepared from 18 
donors were purchased from Xenotech (Tokyo). 
Preparation of microsomes from mice 
Liver microsomes 
Liver tissues were homogenized in ice-cold 1.15% KCl, and microsomes were 
isolated by differential centrifugation as described previously [25]. Briefly, liver homogenate 
was centrifuged at 9,000g for 20 min at 4ºC. The resultant supernatant was then ultracentrifuged 
at 105,000g for 1 hr at 4ºC. The microsomal pellet was washed and resuspended in 100 mM 
sodium phosphate buffer (pH 7.4), and stored at -80ºC until analysis. Protein concentrations 
were determined using a DC protein assay kit (Bio-Rad, Hercules, CA, USA) according to the 
manufacturer’s instructions. 
Intestinal microsomes 
 The extraction of intestinal microsomal fraction was adapted from previous reports 
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[26,27]. After excision of the small intestine, a 10-cm segment of the upper part of the small 
intestine was immediately placed on an ice-cold stainless dish and cut longitudinally, then 
washed with ice-cold phosphate-buffer saline (PBS) by gentle swirling. The cut segment of 
small intestine was placed on ice-cold PBS (pH 7.2) containing 1.5 mM EDTA, 3 U/mL heparin 
and 0.5 mM dithiothretiol for 20 min to loose the mucosal cells. Subsequently, the mucosal cells 
were scraped off with a micro-cover glass and centrifuged at 2,000g for 10 min at 4ºC. The 
centrifuged mucosal cells were added with 4 volumes of ice-cold 50 mM Tris-HCl buffer (pH 
7.4) containing 150 mM KCl, 1mM EDTA, 1 mg/mL trypsin inhibitor, protease cocktail 
inhibitor (Calbiochem, La Jolla, CA, USA) and 20% (v/v) glycerol, and then homogenized 
using a motor-driven Teflon-tipped pestle (5 strokes at 1,200 rpm). The homogenates were 
centrifuged at 9,000g for 20 min at 4ºC, and the resultant supernatant was centrifuged at 
105,000g for 1 hr at 4ºC. The microsomal pellet was washed, resuspended in 250 mM sucrose 
and stored at -80ºC until analysis. Protein concentrations were determined using a DC protein 
assay kit. 
Western Blot analysis 
 Microsomal fractions (10 µg) of livers and small intestines were separated on 10% 
polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. After 30 
min-incubation with blocking buffer (0.05% Tween 20 in PBS containing 3% BSA), the 
membrane was probed for 1 h at room temperature using a polyclonal goat anti-rat CYP3A2 
(Daiichi Pure Chemicals Co., LTD., Tokyo), which can detect both mouse and human CYP3A. 
A monoclonal mouse anti-human β-actin (Sigma-Aldrich), which can detect mouse β-actin, was 
used as the primary antibody of internal control for sample loading. The primary antibody was 
diluted 1000-fold or 3000-fold in 0.05% Tween 20 in PBS containing 3% BSA for anti-rat 
CYP3A2 antibody or anti-human β-actin antibody, respectively. After washing, the membrane 
was incubated with peroxidase-conjugated second antibody for 1 h at room temparature. The 
secondary antibodies used were anti-goat IgG (Sigma) and anti-mouse IgG (Sigma) for anti-rat 
CYP3A2 and anti-human β-actin antibodies, respectively, and diluted 5000-fold with 0.05% 
Tween 20 in PBS containing 3% BSA. The expression of CYP3A and β-actin proteins was 
consequently detected by an enhanced chemiluminescence method using ECLTM Western 
Blotting Detection Reagent (GE Healthcare, Buckingham, UK) and LAS-1000plus (Fujifilm, 
Tokyo). 
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Assay of enzyme activity 
The basic incubation mixture contained liver or intestinal microsomes, 0.1 mM 
EDTA, 100 mM potassium phosphate buffer (pH 7.4), an NADPH-generating system (0.5 mM 
NADP+, 2 mM glucose-6-phosphate, 1 IU/ml glucose-6-phosphate dehydrogenase, 4 mM 
MgCl2), and substrate (200 µM TRZ or 5 µM ethoxyresorufin), in a final volume of 250 µL. The 
concentrations of microsomal proteins and incubation times used were selected from the linear 
range of metabolite formation as shown in Appendix 1 for TRZ-hydroxylase activity and legend 
of Fig. 5 for ethoxyresorufin O-deethylase activity. The mixtures were preincubated for 1 min at 
37ºC, and the reactions were initiated by addition of the 25 µL of NADPH-generation system. 
Incubation was stopped by addition of 100 µL of acetonitrile, followed by addition of 50 µL of 1 
µg/mL oxazepam in methanol for TRZ-hydroxylase activity or 10 µM methoxyresorufin in 
dimethyl sulfoxide for ethoxyresorufin O-deethylase activity as an internal control. The mixture 
were centrifuged at 15,000 rpm for 5 min to remove protein, and supernatants were subjected to 
high-performance liquid chromatography (HPLC) for determination of respective metabolites as 
described below 
HPLC analysis 
TRZ-hydroxylase activity 
The determination of 1-OH TRZ and 4-OH TRZ was carried out using a Hitachi 
L-7000 model of HPLC system (Tokyo) containing of an L-7400 UV detector and a CAPCELL 
PAK C18 UG120 column (4.6 mm x 250 mm, 5 µm; Shiseido, Tokyo). The mobile phase 
consisted of 10 mM potassium phosphate buffer (pH 7.4), acetonitrile and methanol (60/30/10, 
v/v/v), at a flow rate of 1.0 mL/min. The eluent was monitored at a wavelength of 220 nm.  
Ethoxyresorufin O-deethylase activity 
 The determination of resorufin was carried out using a Hitachi L-7000 model of 
HPLC system containing an L-7480 FL detector and a TSKgel-ODS-100Z column (4.6 mm x 
150 mm, 5 µm; Tosoh, Tokyo). The mobile phase consisted of 20 mM potassium phosphate 
buffer (pH 7.4) and acetonitrile (45/55, v/v) containing 2.5 mM tetra-n-octylammonium 
bromide (TCI-EP, Tokyo), at a flow rate of 1.0 mL/min. The excitation and emission 
wavelengths of the fluorescence detector used were 530 and 580 nm, respectively. 
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Kinetics of TRZ metabolism 
 Liver microsomes (0.1 mg/mL) or intestinal microsomes (0.25 mg/mL) of WT mice, 
PCN-treated CYP3A-HAC mice or humans were incubated with several concentrations of TRZ 
(25-750 µM) in the presence of an NADPH-generating system at 37ºC for 20 or 30 min for liver 
or intestinal microsomes, respectively, in a final volume of 250 µL. The formation of 1’-OH 
TRZ and 4-OH TRZ was determined by HPLC as described above. 
Kinetic parameters for the formation of 1’-OH and 4-OH TRZ (Vmax, Km and Ks) 
were determined by nonlinear least-squares method using DeltaGraph 5 (Red Rock Software, 
Salt Lake, UT, USA) according to the following equations. The kinetics of 1’-OH TRZ and 
4-OH TRZ formation in the liver and intestinal microsomes of humans and CYP3A-HAC mice 
were analyzed by normal Michaelis-Menten kinetic model (eq. 1).  
          V = Vmax?S/(Km?S)                              (1) 
For WT mice, data of 4-OH TRZ in the liver microsomes and 1’-OH TRZ and 4-OH 
TRZ in intestinal microsomes were also analyzed using eq. 1, excepting for the data of 1’-OH 
TRZ in the liver microsomes were analyzed by the Michaelis-Menten kinetic model with a 
noncompetitive substrate inhibition model as described previously [23] (eq. 2).  
    V = Vmax?S/[Km?S?(1?S/Ks)]                          (2) 
Immunoinhibition of TRZ metabolism 
 Immunoinhibition assay of TRZ metabolism was performed by preincubation of liver 
or intestinal microsomes (25 µg) of WT mice, CYP3A-HAC mice or humans in the presence or 
absence of the specific antibody raised against CYP3A4 (2.5 µL; BD Gentest) for 10 min at 
room temperature in a final volume of 25 µL. The preincubation mixtures were then diluted 
with the reaction mixture containing 200 µM TRZ, and the reactions were started by addition of 
the NADPH-generating system in a final volume of 250 µL. Samples were incubated for an 
additional 20 min at 37ºC. All incubations were performed in two independent determinations. 
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I-III: Results 
Expression of human CYP3A4 mRNA in the liver and intestine of CYP3A-HAC mice 
 As shown in Fig. 1, CYP3A4 mRNA was expressed in both the liver and 
intestine of CYP3A-HAC mice. In addition, the expression level of CYP3A4 mRNA in 
the liver of CYP3A-HAC mice was remarkably increased by 87 folds after the treatment 
with PCN, a typical CYP3A inducer. In contrast, the expression of CYP3A4 mRNA was 
not detected in both liver and intestine of the untreated and PCN-treated CYP3A-KO 
mice. 
   (A) Liver                          (B) Intestine 
 
 
 
 
 
 
 
Fig. 1. Expression of human CYP3A4 mRNA in the liver (A) and intestine (B) of 
CYP3A-KO and CYP3A-HAC mice.  
The expression level of CYP3A4 mRNA in the liver (A) and intestine (B) of CYP3A-KO mice and 
CYP3A-HAC mice treated with corn oil (control) or PCN was measured by real-time PCR. Data are 
expressed as relative expression level to the expression level of mouse GAPDH, and are means ± S.E. of 
3-4 mice from three independent measurements, each performed in duplicate. ND, not detectable. 
Expression of CYP3A proteins in the liver and intestine of CYP3A-HAC mice 
 As shown in Fig. 2, the expression of CYP3A proteins was detected in both 
the liver and intestine of CYP3A-HAC mice. After the treatment with PCN, the 
expression of CYP3A proteins in the liver of the CYP3A-HAC mice was remarkably 
increased. In contrast to CYP3A-HAC mice, the expression of CYP3A proteins was 
negligible in both the liver and intestine of CYP3A-KO mice, and no induction effect of 
PCN on the expression of CYP3A proteins was found in both livers and intestines. 
0.425 
0.870 
ND ND 
3.212 
 
ND ND 
0.037 
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       (A) Liver                        (B) Intestine 
 
 
 
 
 
 
Fig. 2. Expressions of CYP3A proteins in the liver (A) and intestine (B) of WT, 
CYP3A-KO and CYP3A-HAC mice.  
Western blot analyses of CYP3A proteins expression in the liver and intestine of WT, CYP3A-KO and 
CYP3A-HAC mice treated with corn oil (control) or PCN compared with humans. The 10 µg of pooled 
liver or intestinal microsomes was loaded per lane. Blots were probed with antibody raised against rat 
CYP3A2, which can detect both human and mouse CYP3A. The expression level of β-actin was used as 
an internal control for sample loading. The expression of CYP3A and β-actin proteins was detected by 
using an enhanced chemiluminescence method. 
 
 
Enzyme activities in the liver and intestine of CYP3A-HAC mice 
To examine whether CYP3A proteins expressed in the liver and intestine of 
CYP3A-HAC mice were functional, the formation of 1’-OH TRZ and 4-OH TRZ was 
determined as the marker of CYP3A activities. As shown in Fig. 3, both the formation 
of 1-OH TRZ and 4-OH TRZ was detected in liver and intestinal microsomes of the WT 
mice, but were markedly low in liver and intestinal microsomes of the CYP3A-KO 
mice. On the other hand, the formation of 1’-OH TRZ and 4-OH TRZ was significantly 
detected in liver and intestinal microsomes of the CYP3A-HAC mice, and the CYP3A 
activities in the intestinal microsomes of CYP3A-HAC mice were comparable to those 
in humans and WT mice. After treatment with PCN, the formation of 1’-OH TRZ and 
4-OH TRZ was elevated in the liver and intestinal microsomes of CYP3A-HAC mice as 
observed in WT mice, whereas no induction effect of PCN on CYP3A acitivities was 
observed in both the liver and intestinal microsomes of the CYP3A-KO mice (Fig. 4).  
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(A) Liver 
 
 
 
 
 
 
 
 
 
 
   (B) Intestine 
 
 
 
 
 
 
 
 
Fig. 3. Metabolic activities of CYP3A enzymes expressed in the liver (A) and 
intestine (B) of CYP3A-HAC mice. 
Metabolic activities of CYP3A enzymes in microsomal fractions obtained from liver (A) and intestine (B) 
of WT, CYP3A-KO, CYP3A-HAC mice and humans were determined using TRZ 200 µM as a CYP3A 
probe. The concentrations of microsomal proteins and incubation times used were listed in Appendix 1. 
The formation of 1’-OH TRZ and 4-OH TRZ was determined by using HPLC as described in Material 
and Methods. Data are shown as means of three independent experiments (± S.D.), each performed in 
duplicate.  
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(A) Liver 
 
 
 
 
 
 
 
 
 
  (B) Intestine 
 
 
 
 
 
 
 
Fig. 4. Induction of CYP3A activities by PCN treatment in the liver (A) and 
intestine (B) of CYP3A-HAC mice. 
Metabolic activities of CYP3A enzymes in microsomal fractions from liver (A) and intestine (B) of WT, 
CYP3A-KO and CYP3A-HAC mice treated with corn oil (control) or PCN were determined using TRZ 
200 µM as CYP3A probe. The concentration of microsomal proteins and incubation times used were 
listed in Appendix 1. The formation of 1’-OH TRZ and 4-OH was determined by HPLC as described in 
Material and Methods. Data are shown as means of three independent experiments (± S.D.).  
 
To confirm that the knockout of mouse Cyp3a subfamily did not decrease the 
activity of the other enzymes besides CYP3A, we determined ethoxyresorufin 
O-deethylase activity as the marker of CYP1A activity. As shown in Fig. 5, 
ethoxyresorufin O-deethylase activities in the liver of CYP3A-KO and CYP3A-HAC 
mice were comparable to those in WT mice. 
1’-OH TRZ 4-OH TRZ 
4-OH TRZ 1’-OH TRZ 
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Fig. 5. Ethoxyresorufin O-deethylase activities in the liver of WT, CYP3A-KO and 
CYP3A-HAC mice.  
Metabolic activities of CYP1A enzymes in microsomal fractions (0.01 mg/mL) from livers of WT, 
CYP3A-KO and CYP3A-HAC mice were determined using ethoxyresorufin (5 µM) as the CYP1A probe. 
The reaction mixture was incubated at 37? for 5 min. The ethoxyresorufin O-deethylase activity was 
determined by HPLC as described in Material and Methods. Data are shown as means of three 
independent experiments (± S.D.), each performed in duplicate.  
Kinetics of TRZ metabolism 
Michaelis-Menten plots of TRZ metabolism in the liver and intestinal 
microsomes of WT mice, PCN-treated CYP3A-HAC mice and humans are shown in 
Fig. 6, and kinetics parameters for TRZ metabolism are listed in Table 1. In the liver 
microsomes of WT mice, the formation of 4-OH TRZ obeyed normal Michaelis-Menten 
kinetic model, whereas the formation of 1’-OH TRZ did not obey the normal 
Michaelis-Menten kinetic model but could be fitted with the Michaelis-Menten kinetic 
model with noncompetitive substrate inhibition model. In contrast, the formation of 
both 1’-OH TRZ and 4-OH TRZ in the liver microsomes of CYP3A-HAC mice could 
be fitted with the normal Michaelis-Menten kinetic model, which was consistent with 
those in human livers. In the low concentrations of TRZ, the formation of 1’-OH TRZ 
was remarkably higher than the formation of 4-OH TRZ in the liver microsomes of WT 
mice, whereas almost the same formation rates of 1’-OH TRZ and 4-OH TRZ were 
observed in the liver microsomes of CYP3A-HAC mice and humans. In addition, Km 
values for both pathways in the liver microsomes of CYP3A-HAC mice and humans 
were much higher than those in WT mice. In contrast, ratios of intrinsic clearance 
(Vmax/Km) for 1’-OH TRZ and 4-OH TRZ formations in liver microsomes of 
CYP3A-HAC mice and humans were 3-fold lower than those in WT mice (2.73 and 
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2.61 vs. 8.39). Similarly, ratios of intrinsic clearance of 1’-OH pathway in liver 
microsomes compared to intestinal microsomes in CYP3A-HAC mice and humans were 
3- and 4-fold lower than those in WT mice (7.16 and 4.92 vs. 21.2), respectively.    
 
          (A) WT mice 
 
 
 
 
 
 
 
 
(B) CYP3A-HAC mice           (C) Human 
 
 
 
 
 
 
 
 
Fig. 6. Michaelis-Menten plots of TRZ metabolism in the liver and intestine of WT 
mice (A), CYP3A-HAC mice (B) and humans (C).  
TRZ (25-750 µM) was incubated for 20 or 30 min with liver (0.1 mg/mL) or intestinal (0.25 mg/mL) 
microsomes, respectively, of WT mice, PCN-treated CYP3A-HAC mice or humans. The kinetic 
parameters for 1’-OH TRZ and 4-OH TRZ formation were estimated by nonlinear least-squares method 
using a normal Michaelis-Menten kinetic model, excepting for the formation of 1’-OH TRZ in liver 
microsomes of WT mice that was analyzed by a Michaelis-Menten kinetic model with a noncompetitive 
substrate inhibition model as described in Materials and Methods. The data are shown as means of three 
independent determinations, excepting for the data of intestinal microsomes of CYP3A-HAC mice are 
shown as means of two independent determinations. 
 
 
 
 
  
Table 1. Kinetic parameters for triazolam metabolism in liver and intestinal microsomes of WT mice, CYP3A-HAC mice and humans 
Vmax, Km and Ks values were calculated by nonlinear least-squares method using models described in Materials and Methods by using the 
data shown in Fig 6. Numbers in parentheses represent S.D. from three determinations. 
Vmax Km Ks Clint (Vmax/Km) % of total Clint Ratio Clint Ratio of Clint Ratio of Clint Sample 
(nmole/min/mg protein) (µM) (µM) µL/min/mg protein ?  1’-OH/4-OH?  Li/In for 1'-OH TRZ Li/In for 4-OH TRZ 
WT         
Liver         
1'-OH-TRZ 4.24 (0.55) 19.8 (1.34) 945 (80.9) 214 89.4 8.39 21.2 5.66 
4-OH-TRZ 4.64 (0.69) 182 (22.5)  25.5 10.6    
Intestine         
1'-OH-TRZ 0.42 (0.17) 41.6 (8.56)  10.1 69.2 2.25   
4-OH-TRZ 2.23 (1.02) 494 (98.9)  4.51 30.8    
         
CYP3A-HAC         
Liver         
1'-OH-TRZ 13.0 (1.41) 75.5 (1.38)  172 73.2 2.73 7.16 8.26 
4-OH-TRZ 47.6 (8.84) 754 (65.4)  63.1 26.8    
Intestine         
1'-OH-TRZ 1.42 59.1  24.0 75.9 3.15   
4-OH-TRZ 4.69 613  7.64 24.1    
         
Human         
Liver         
1'-OH-TRZ 1.73 (0.26) 67.6 (3.92)  25.6 72.3 2.61 4.92 4.45 
4-OH-TRZ 5.90 (0.68) 601 (80.4)  9.81 27.7    
Intestine         
1'-OH-TRZ 0.44 (0.13) 84.8 (21.5)  5.20 70.2 2.36   
4-OH-TRZ 1.78 (0.55) 806 (255)  2.20 29.8 ?  ?  ?  
 - 19 - 
Immunoinhibition of TRZ metabolism by anti-human CYP3A4 antibody 
Fig. 7 shows results of immunoinhibition assays using a monoclonal antibody 
raised against human CYP3A4. The anti-human CYP3A4 antibody did not inhibit TRZ 
metabolism in liver and intestinal microsomes of the WT mice. In contrast, the 
anti-human CYP3A4 antibody inhibited TRZ metabolism in liver and intestinal 
microsomes of the CYP3A-HAC mice treated with or without PCN, which was 
consistent with results in humans.  
 
    (A) Liver                      (B) Intestine 
 
 
 
 
 
 
 
 
Fig. 7. Immunoinhibition of TRZ metabolism in the liver (A) and intestine (B) of 
CYP3A-HAC mice by anti-human CYP3A4 antibody.  
Liver or intestinal microsomes of WT mice, CYP3A-HAC mice (treated with corn oil or PCN) or humans 
were preincubated with the monoclonal antibody raised against human CYP3A4 (10 µL/100 µg 
microsomal proteins) at room temperature for 10 min. The preincubation mixture was then added to the 
reaction mixture containing TRZ (200 µM) and an NADPH-generating system and incubated at 37ºC for 
10 min or 20 min for liver and intestinal microsomes, respectively. Data are shown as % of control 
relative to the activity in the absence of serum and are the means of two independent determinations. 
 
 - 20 - 
I-IV: Discussion 
To overcome problems of species differences in CYP3A, the CYP3A-HAC 
mouse line carrying the entire human CYP3A cluster (CYP3A4, CYP3A5, CYP3A7 and 
CYP3A43) has been constructed by HAC vector system. In the present study, we 
demonstrated that human CYP3A mRNA and proteins were expressed in both the liver 
and intestine of the CYP3A-HAC mice, but were negligible in the CYP3A-KO mice 
(Figs. 1 and 2). In addition, the kinetic profiles of TRZ metabolism in both liver and 
intestine of the CYP3A-HAC mice were comparable to those in humans (Fig. 6 and 
Table 1), indicating that CYP3A genes were expressed as the functional human CYP3A 
enzymes in CYP3A-HAC mice. The results of the present study suggest the possibility 
to use CYP3A-HAC mouse line as an in vivo model for study of human 
pharmacokinetics. 
TRZ was used as the CYP3A probe to examine the functional expression of 
CYP3A enzymes in CYP3A-HAC mouse line, since it has been reported that TRZ was 
specifically metabolized by CYP3A in both humans and mice [23]. As we expected, the 
significant formation of TRZ metabolites was observed in both the liver and intestinal 
microsomes of CYP3A-HAC mice, but not in CYP3A-KO mice (Fig. 3). In addition, 
the formation of TRZ metabolites in both liver and intestine of CYP3A-HAC mice was 
elevated by the treatment with PCN, a typical CYP3A inducer (Fig. 4). Consistent with 
results of CYP3A activities, the expression of CYP3A4 mRNA and CYP3A proteins 
was significantly detected and inducible by PCN treatment in both liver and intestine of 
CYP3A-HAC mice, but not in CYP3A-KO mice (Figs. 1 and 2). These results indicated 
that CYP3A enzymes were expressed and inducible by CYP3A inducer in the liver and 
intestine of CYP3A-HAC mice but not in CYP3A-KO mice. 
The previous report showed that the metabolism and pharmacokinetics of 
midazolam in Cyp3a(-/-) mice were not significantly different from those in WT mice, 
because the up-regulated mouse CYP2C enzymes could be involved in midazolam 
metabolism in Cyp3a(-/-) mice [24]. In our CYP3A-KO mouse line, the up-regulation of 
CYP2C mRNAs was also observed (data not shown). In addition, it has been reported 
that the up-regulation of CYP2C mRNAs in Cyp3a(-/-) mice could be compensated by 
the expression of CYP3A in CYP3A4-transgenic mice [24,28]. Consistently, we found 
that the up-regulated CYP2C mRNA levels in CYP3A-HAC mice were lower than 
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those in CYP3A-KO mice (data not shown). We also found that midazolam metabolism 
was significantly observed in both the untreated and PCN-treated CYP3A-KO mice, 
which could not be inhibited by ketoconazole (2.5 µM), a specific inhibitor for CYP3A 
(data not shown). Although TRZ metabolism was not completely diminished in 
CYP3A-KO mice, the residual level was markedly low compared to that in midazolam 
metabolism. These results revealed that the involvement of the up-regulated CYP2C in 
triazolam metabolism in CYP3A-KO mice was less than that in midazolam metabolism, 
suggesting that TRZ is the suitable CYP3A probe for characterization of CYP3A 
enzymes expressed in CYP3A-HAC mouse line. 
 In the present study, we demonstrated that the kinetic profiles of TRZ 
metabolism in liver and intestinal microsomes of CYP3A-HAC mice were comparable 
to those in humans, but were different from those in WT mice (Fig. 6 and Table 1). 
Although TRZ was specifically metabolized by CYP3A to yield main metabolites, 
1’-OH TRZ and 4-OH TRZ, in both humans and mice, it has been reported that there 
are species differences in the kinetics of TRZ metabolism between humans and mice 
[23]. Consistently, we observed that the kinetics of 1’-OH TRZ formation in liver 
microsomes of WT mice exhibited the characteristics of substrate inhibition when the 
high concentrations of TRZ were used (Ks = 945 ? 80.9 µM, Table 1). In contrast, the 
kinetics of 1’-OH TRZ formation in the liver microsomes of CYP3A-HAC mice did not 
show the characteristics of substrate inhibition. It could be fitted using the normal 
Michealis-Menten kinetics model, which was similar to those in human liver 
microsomes. In addition, the Km values for the formation of both 1’-OH and 4-OH TRZ 
in the liver and intestinal microsomes of CYP3A-HAC mice were comparable to those 
in humans, but were much higher than those in WT mice. Furthermore, anti-human 
CYP3A antibody could inhibit TRZ metabolism in liver and intestine of CYP3A-HAC 
mice and humans but not in WT mice (Fig. 7), suggesting that TRZ metabolism in 
CYP3A-HAC mice mediated by the functional human CYP3A enzymes. Taken together, 
these results indicated that CYP3A proteins were expressed as functional human 
CYP3A enzymes in both the liver and intestine of CYP3A-HAC mice, suggesting the 
possibility to use CYP3A-HAC mice as the models for study of human 
pharmacokinetics. 
Although it has long been realized that the liver is the major site of first-pass 
metabolism of drugs, the intestine would also be the important determinant of orally 
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administered drugs [29]. A recent comprehensive study demonstrated that CYP3A 
subfamily is the major CYP expressed in the intestine [30]. Although the total amount 
of intestinal CYP3A is relatively low compared with that in the liver, it has been 
reported that intestinal CYP3A is able to contribute significantly to the overall first-pass 
metabolism of many drugs including TRZ [13]. However, an appropriate model for 
study of drug metabolism mediated by the human intestinal CYP3A is lacking. In the 
present study, we demonstrated that CYP3A activities in the intestine of untreated 
CYP3A-HAC mice were comparable to those in humans (Fig. 3B). These results 
suggest that the high level of CYP3A activities in the intestines of CYP3A-HAC mouse 
line yields useful model for study of the first-pass drug metabolism mediated by 
CYP3A enzymes in the intestine for orally administered drugs.  
Compared to the expression levels and enzyme activities of CYP3A in the 
intestine of CYP3A-HAC mice, CYP3A-HAC mice exhibited low expression levels and 
enzyme activities of the hepatic CYP3A (Figs. 1A, 2A and 3A). Although the 
mechanism(s) underlying the low expression of hepatic CYP3A in the untreated 
CYP3A-HAC mice is unclear, the following reasons may be involved in these findings. 
The first possibility is that the down-regulation of hepatic CYP3A expression by growth 
hormone-mediated mechanism may occur in adult male CYP3A-HAC mice used in the 
present study. Recently, it has been reported that the expression of CYP3A4 was 
decreased in the CYP3A4-transgenic mouse lines after 6-weeks old of male mice 
[12,31,32]. The difference in secretory pattern of growth hormone between the adult 
male and female mice involved in the declined expression of hepatic CYP3A4 in 
puberty male CYP3A4-transgenic mice. Since CYP3A-HAC mice used in the present 
study were 9-18 weeks old of male mice, the low expression of hepatic CYP3A in 
CYP3A-HAC mice might be explained by the down-regulation of hepatic CYP3A 
expression after sexual maturity in CYP3A-HAC male mice. In contrast to hepatic 
CYP3A expression, it has been reported that no down-regulation of intestinal CYP3A 
expression was observed in the adult male CYP3A4-transgenic mice [10]. Consistently, 
CYP3A expression and activities were highly observed in the intestines of the adult 
CYP3A-HAC male mice used in this study (Figs. 1B, 2B and 3B). These finding 
revealed that the effect of growth hormone secretory pattern in male mice on CYP3A 
expression might be tissue specific. Further studies on the impact of age on hepatic 
CYP3A expression in CYP3A-HAC mouse line will be useful to yield the most 
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appropriate animal model to study human pharmacokinetics mediated by CYP3A. The 
second possibility is the different gene-regulation of CYP3A between humans and mice. 
It has been reported that hepatocyte nuclear factor-4?, pregnane X receptor (PXR), 
constitutive androstane receptor and vitamin D receptor are involved in the regulation of 
CYP3A expression [1,33]. Since there are species differences in response to PXR 
ligands and also constitutive androstane receptor ligands [34], the transcriptional 
regulation of CYP3A genes occurring in the liver of CYP3A-HAC mice may be 
different from that in human liver, which may affect the expression level of hepatic 
CYP3A in the untreated CYP3A-HAC mice. Another possibility is the 
miRNA-mediated mechanism(s) of CYP3A suppression in the liver of adult male 
CYP3A-HAC mice. The miRNAs have been identified as an extensive class of 
endogenous siRNA molecules that control the expression of targeted genes through the 
inhibition of protein synthesis or the cleavage of mRNA in specific cells at certain 
developmental stage among different species [35,36]. Recently, it has been reported that 
mmu-miR-298 could down-regulate the expression of CYP3A4 by direct targeting in 
3’-untranslated region of CYP3A4 mRNA or indirect targeting via regulation of vitamin 
D receptor [37]. In addition, in the same study, they reported that the expression of 
mmu-miR-298 precursor was increased in the liver of male CYP3A4-transgenic mice 
after puberty, whereas it was decreased in the liver of WT mice after puberty. Therefore, 
miRNA-mediated mechanism cannot be ruled out for the observed low hepatic CYP3A 
expression in the adult male CYP3A-HAC mice. 
In conclusion, CYP3A-HAC mouse line is the first model carrying the entire 
human CYP3A cluster. The functional human CYP3A enzymes were expressed in both 
liver and intestine of CYP3A-HAC mice and the kinetic profiles of TRZ metabolism in 
CYP3A-HAC mice were well comparable to those in humans. Although the low 
expression level of hepatic CYP3A in CYP3A-HAC mice remains to be developed to 
yield better models and further in vivo studies are needed, the results of the present 
study suggest that CYP3A-HAC mouse line would be the useful in vivo tool for study 
of human pharmacokinetics.  
 - 24 - 
 
 
 
 
 
 
 
 
 
Chapter II 
 
 
 
Application of CYP3As-humanized mice to study drug-drug 
interaction mediated by mechanism-based inactivation of CYP3A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 25 - 
II-I 
Species differences in mechanism-based inactivation of CYP3A     
in humans, rats and mice 
II-I-I: Introduction 
DDI arising from inhibition of CYP3A may lead to serious adverse drug 
reaction [38]. In the inhibition of CYP3A, MBI has long-term effect on 
pharmacokinetic DDI since inactivation of CYP3A by formation of a stable complex 
with a metabolite is irreversible and synthesis of a new enzyme is required to restore the 
functional deficit [3,39]. Some drugs (e.g., mibefradil) have been withdrawn from the 
market due to unacceptable risk of potentially dangerous DDI resulting from 
inactivation of CYP3A [3,4]. Consequently, attention has been paid to the prediction of 
MBI arising from CYP3A in the development of new drug entities to avoid dangerous 
DDI.  
To assess the potential of drug candidates to cause MBI of CYP3A, in vitro 
experiments have been performed to evaluate the degree of time- and 
concentration-dependent inactivation using human liver microsomes, cDNA-expressed 
enzymes and human hepatocytes [4,40,41]. Based on inactivation parameters, models 
for predicting the degree of clinical in vivo DDI have been developed; however, the 
accuracy of prediction is uncertain [41-44]. For in vivo studies, little is known about the 
accuracy of prediction of the potential of MBI-mediated DDI using animals, because 
species differences in CYP3A inactivation via MBI have been less studied.  
Mechanism-based inactivation is common for CYP3A substrates that contain 
an amine functional group and undergo N-dealkylation [45]. Macrolide antibiotics, such 
as erythromycin, clarithromycin and troleandomycin, and calcium channel blockers, 
such as diltiazem and nicardipine, are well known CYP3A inhibitors via MBI in 
humans [45-50]. Each of them possesses a tertiary amine that can be metabolized to a 
nitroso group and forms a stable metabolic intermediate complex with the heme of 
human CYP3A [42,50]. However, it is unclear whether MBI potencies of CYP3A 
inhibitors in humans are comparable to those in experimental animals. 
The present study examines species differences in MBI of CYP3A between 
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humans and rodents. We compared MBI potencies of representative CYP3A inhibitors 
(erythromycin, clarithromycin, troleandomycin, diltiazem and nicardipine) in human, 
rat and mouse liver microsomes. In addition, we monitored the formation of a metabolic 
intermediate complex and examined possible factors explaining species differences in 
MBI potencies of CYP3A inhibitors.  
 
II-I-II: Materials and Methods 
Chemicals 
Erythromycin, clarithromycin and troleandomycin were purchased from Wako Pure 
Chemicals. Diltiazem and nicardipine were purchased from Sigma-Aldrich. TRZ, 1’-OH TRZ 
and 4-OH TRZ were obtained from the same sources as detailed in Materials and Methods of 
Chapter I. Other reagents were of analytical or HPLC grade and obtained commercially. 
Liver microsomes  
Pooled human liver microsomes prepared from 25-30 donors were purchased from 
BD Gentest. Pooled rat liver microsomes were prepared from 6-week-old male Sprague-Dawley 
rats purchased from Japan SLC Inc. (Shizuoka). Pooled mouse liver microsomes were prepared 
from 9-week-old male C57BL/6Cr mice purchased from Japan SLC Inc. Liver tissues from 
untreated rats (pooled from 3 animals) and mice (pooled from 8 animals) were prepared as 
described in Materials and Methods of Chapter I. 
HPLC analysis for 1’-OH TRZ and 4-OH TRZ  
Determination of 1’-OH TRZ and 4-OH TRZ was carried out using a Hitachi L-7000 
model of HPLC system as described in Materials and Methods of Chapter I.  
Immunoinhibition assay 
Immunoinhibition assay of TRZ metabolism was performed by preincubation of liver 
microsomes of humans, rats or mice (12.5 µg) with 1.25 or 2.5 µL of rabbit polyclonal 
anti-serum for CYP3A2 (Xenotech, Tokyo) or pre-immune rabbit serum for 10 min at room 
temperature in a final volume of 25 µL. The mixtures were diluted with a reaction mixture 
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containing 200 µM TRZ, and the reactions were started by the addition of the 
NADPH-generating system in a final volume of 250 µL. The samples were incubated for an 
additional 20 min at 37ºC. All incubations were performed in two independent determinations. 
Data are expressed as % remaining activity relative to the activity in the absence of serum. 
Mechanism-based inactivation (MBI) by CYP3A inhibitors 
MBI assays were performed as recommended previously [39]. Liver microsomes of 
humans, rats or mice (1 mg/mL) was preincubated at 37ºC with various concentrations of 
inhibitors in reaction mixtures each containing 1 mM NADPH instead of the 
NADPH-generating system. At various times, aliquots of the preincubation mixtures (25 µL) 
were diluted 10-fold with fresh reaction mixture containing 1 mM NADPH and 400 µM TRZ to 
a final volume of 250 µL. A saturating concentration of TRZ was used to measure the remaining 
catalytically active CYP3A. The reactions were continued for 5 min and terminated by 
acetonitrile as described above. Data were corrected for loss of activity in control incubation (no 
inhibitor) at each time. All incubations were performed in two independent determinations. 
To estimate inactivation parameters, the natural logarithm of the percentage of 
remaining activity was plotted against preincubation time. The observed inactivation rate 
constants (kobs) were determined from the slopes of the initial linear decline in activity at each 
inhibitor concentration. The parameters kinact and KI were obtained from a direct plot of inhibitor 
concentration (I) versus kobs according to the nonlinear least-squares method using DeltaGraph 5 
(Red Rock Software, Salt Lake, UT) according to the following equation: 
kobs = kinact ? I/(KI ? I), 
where kobs is the pseudo first-order rate constant of inactivation at the inhibitor concentration (I), 
kinact is the maximum inactivation rate constant, and KI is the inhibitor concentration when the 
rate constant of inactivation reaches half of kinact. 
 
Formation of P450-Iron(II)-metabolic intermediate complex 
The incubation mixture contained liver microsomes of humans (2 mg/mL), rats (3 
mg/mL) or mice (3 mg/mL) in 100 mM phosphate buffer (pH 7.4), 10 mM MgCl2 and 1 mM 
NADPH in a final volume of 2 mL. Equal volumes were allotted to sample and reference 
cuvettes and a baseline was recorded. Erythromycin (100 µM), clarithromycin (100 µM), 
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troleandomycin (20 µM), diltiazem (10 µM) or nicardipine (10 µM) was added to the sample 
cuvette, whereas the reference cuvette received an equal volume of a vehicle (methanol, final 
concentration of less than 1%). Difference spectra for the reference and sample cuvettes were 
recorded using a dual-beam spectrophotometer (Hitachi U-3300) by scanning from 400 to 500 
nm. The difference spectra were recorded immediately (0 min) after addition of the inhibitor 
and at 20-min incubation at 37ºC. 
Reversible inhibition by CYP3A inhibitors 
Liver microsomes of humans, rats or mice (0.1 mg/mL) was simultaneously 
incubated with 100 µM TRZ and several concentrations of inhibitors in the presence of the 
NADPH-generating system for 5 min at 37ºC in a final volume of 250 µL. Since the period of 
product formation was kept brief and inhibitors were coincubated with a substrate as reported 
previously, inhibition parameters were considered to reflect primarily the affinity of the 
inhibitor to CYP3A enzymes [50,51] The activity of 4-OH TRZ formation was then determined 
by HPLC as described above and expressed as a percentage relative to the activity in the 
absence of inhibitors. All incubations were performed in two independent determinations. The 
concentration of the inhibitor producing 50% decrease in the activity of CYP3A (IC50 value) 
was estimated by nonlinear regression analysis using DeltaGraph 5, according to the following 
equation [51]: 
A = Amax?[1?(C/C?IC50)], 
where A and Amax are the percentage of activity (relative to control) measured in the presence of 
inhibitors (at concentration C) and in the absence of inhibitors, respectively.  
 
II-I-III: Results 
CYP3A specificity of TRZ metabolism in liver microsomes of humans, rats and mice 
Fig. 8 shows the remaining activity of TRZ metabolism in the presence of 
anti-rat CYP3A2 antibody or pre-immune serum. In human and mouse liver 
microsomes, the formation of 1’-OH TRZ and 4-OH TRZ was almost completely 
inhibited by anti-rat CYP3A2 antibody. The formation of 4-OH TRZ in rat liver 
microsomes was also almost completely inhibited by anti-rat CYP3A2 antibody, but 
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11% of 1’-OH TRZ formation was not inhibited. These results suggest that TRZ 
metabolism is highly specific to CYP3A in liver microsomes of humans, rats and mice; 
however, 4-OH TRZ formation appears to be a more suitable marker for CYP3A 
activity. Therefore, we monitored the formation of 4-OH TRZ as a marker of CYP3A 
activity in the following experiments. 
 
    (A) Human           (B) Rat              (C) Mouse 
 
 
 
 
 
Fig. 8. Immunoinhibition of TRZ metabolism by anti-CYP3A serum in liver 
microsomes of humans (A), rats (B) and mice (C).  
After 10-min preincubation of liver microsomes of humans, rats or mice at room temperature with the 
rabbit polyclonal anti-serum for CYP3A2 (IMM) or pre-immune rabbit serum (PRE), the preincubation 
sample was diluted with reaction mixture and reaction was started by addition of an NADPH-generating 
system. The mixture was subsequently incubated for 20 min at 37ºC. The final concentration of TRZ used 
was 200 µM. Data are shown as % remaining activity relative to the activity in the absence of serum and 
are the means of two determinations. 
MBI effects of CYP3A inhibitors on CYP3A activity 
 To examine species differences in MBI of CYP3A for humans and rodents, 
we compared MBI potencies of representative CYP3A inhibitors (erythromycin, 
clarithromycin, troleandomycin, diltiazem and nicardipine) in liver microsomes of 
humans, rats and mice. The effects of time- and concentration-dependent inactivation on 
the formation of 4-OH TRZ by CYP3A inhibitors are shown in Fig. 9, and estimated 
parameters for inactivation (KI, kinact and kinact/KI ratio) are listed in Table 2. In human 
liver microsomes, all CYP3A inhibitors studied inhibited the formation of 4-OH TRZ in 
a time- and concentration-dependent manner, showing a representative pattern of MBI. 
In contrast, the inactivation effects of CYP3A inhibitors on the formation of 4-OH TRZ 
in liver microsomes of rats and mice were different from those in liver microsomes of 
humans. Notably, the inactivation effects of erythromycin and clarithromycin in rat and 
mouse liver microsomes were remarkably weaker than those in human liver microsomes. 
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In rat liver microsomes, erythromycin caused no significant time-dependent inactivation 
so that parameters for the inactivation of enzymes could not be estimated. The kinact and 
the kinact/KI ratio in mouse liver microsomes for erythromycin were approximately 
4-fold lower than those in human liver microsomes. Similarly, kinact and kinact/KI ratios 
for clarithromycin in rat and mouse liver microsomes were much lower than those in 
human liver microsomes. On the other hand, kinact/KI ratios for troleandomycin and 
diltiazem were comparable between human and mouse liver microsomes, whereas the 
kinact/KI ratio in rat liver microsomes was lower than in human or mouse liver 
microsomes. In all species, nicardipine showed a high kinact/KI ratio and nearly the same 
kinact. 
Formation of P450-Iron(II)-metabolic intermediate complex 
 The formation of a metabolic intermediate complex with CYP3A can be 
detected by display of a spectrum with absorbance maximum around 455 nm, a 
characteristic Soret peak [45]. To investigate possible mechanistic differences in the 
inactivation of CYP3A for liver microsomes of humans, rats and mice, we monitored 
the formation of a metabolic intermediate complex by scanning spectral changes 
between 400-500 nm. As shown in Fig. 10A, representative spectral changes with a 
Soret peak were observed when erythromycin or clarithromycin was incubated with 
human liver microsomes. Similarly, incubation of troleandomycin, diltiazem and 
nicardipine with liver microsomes of rats or mice resulted in spectral change (Figs. 10B 
and 10C). In contrast, incubation of erythromycin and clarithromycin with liver 
microsomes of rats or mice showed no spectral change. 
 
 
(A) Erythromycin 
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(B) Clarithromycin 
 
 
 
 
 
(C) Troleandomycin 
 
 
 
 
 
(D) Diltiazem 
 
 
 
 
 
(E) Nicardipine 
 
 
 
 
 
 
Fig. 9. Time- and concentration-dependent inhibition of 4-OH TRZ formation by 
CYP3A inhibitors in liver microsomes of humans, rats and mice. 
Microsomes (1 mg/mL) were incubated at 37ºC at several concentrations of erythromycin (A), 
clarithromycin (B), troleandomycin (C), diltiazem (D) or nicardipine (E) in the presence of 1 mM 
NADPH at various times up to 20 min. The incubation sample was then added to fresh incubation mixture 
(10-fold dilution) containing 400 µM TRZ and incubated for another 5 min to assess remaining TRZ 
4-hydroxylase activity. Data are shown as means of two determinations, which were corrected for loss of 
activity in control incubation (no inhibitor) of each time. The unit of inhibitor concentration represented 
in each figure is µM. 
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Table 2. Inactivation parameters for 4-OH TRZ formation by CYP3A inhibitors in liver 
microsomes of humans, rats and mice 
 
Inhibitor Parameter Human Rat Mouse 
KI 5.4 n.c. 6.7 
kinact 0.069 n.c. 0.019 
Erythromycin 
kinact/KI 12.4 n.c. 2.9 
     
KI 16.7 66.2 30.0 
kinact 0.074 0.030 0.024 
Clarithromycin 
kinact/KI 4.4 0.5 0.8 
     
KI 1.8 2.6 0.9 
kinact 0.146 0.030 0.074 
Troleandomycin 
kinact/KI 82.0 11.5 81.7 
     
KI 0.6 6.7 0.6 
kinact 0.029 0.099 0.046 
Diltiazem 
kinact/KI 52.1 14.9 76.3 
     
KI 3.1 1.9 4.0 
kinact 0.305 0.311 0.325 
Nicardipine 
kinact/KI 97.0 161 80.5 
The KI and kinact values were calculated as described in Material and Methods using the data shown in Fig. 
2. The units of KI, kinact and kinact/KI ratio are µM, min-1 and 10-3?min-1?µM-1, respectively. n.c., not 
calculable because of weak inactivation effect. 
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(A) Human 
 
 
 
 
 
 
 
(B) Rat 
 
 
 
 
 
 
 
 
(C) Mouse 
 
 
 
 
 
 
 
 
Fig. 10. Formation of metabolic intermediate complex by CYP3A inhibitors in liver 
microsomes of humans (A), rats (B) and mice (C).  
The incubation mixture contained liver microsomes of humans (2 mg/mL), rats (3 mg/mL) or mice (3 
mg/mL) with 1 mM NADPH. After running baseline, erythromycin (100 µM), clarithromycin (100 µM), 
troleandomycin (20 µM), diltiazem (10 µM) or nicardipine (10 µM) was added to the sample cuvette, 
whereas the reference cuvette received an equal volume of a vehicle. Difference spectra between 
reference and sample cuvettes were recorded using a dual-beam spectrophotometer. Representative 
20-min difference spectra for incubation of inhibitors with liver microsomes of humans, rats and mice are 
shown.  
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Reversible inhibition effects of CYP3A inhibitors on CYP3A activity 
 Since differences in potencies of MBI by CYP3A inhibitors for liver 
microsomes of humans, rats and mice may be partly dependent on differences in 
affinities of inhibitors for CYP3A, we determined reversible inhibition parameter (IC50) 
for each inhibitor as a marker reflecting binding affinity for CYP3A. The relationship 
between inhibitor concentration and uninhibited percentage of the formation of 4-OH 
TRZ in liver microsomes of humans, rats and mice is shown in Fig. 11, and IC50 are 
listed in Table 3. All CYP3A inhibitors studied inhibited the formation of 4-OH TRZ in 
a concentration-dependent manner, but some species differences in IC50 were observed. 
IC50 of erythromycin and clarithromycin observed in rat and mouse liver microsomes 
were much higher than in human liver microsomes, whereas IC50 of diltiazem observed 
in rat and mouse liver microsomes were approximately 3-fold lower than in human liver 
microsomes. IC50 of troleandomycin observed in rat liver microsomes was 
approximately 3-fold higher than in human and mouse liver microsomes. Among the 
CYP3A inhibitors studied, IC50 of nicardipine was lowest for any species (< 2 µM). 
  (A) Human              (B) Rat              (C) Mouse 
 
 
 
 
 
Fig. 11. Reversible inhibition of 4-OH TRZ formation by CYP3A inhibitors in liver 
microsomes of humans (A), rats (B) and mice (C).  
At several concentrations, erythromycin, clarithromycin, troleandomycin, diltiazem, or nicardipine were 
coincubated with microsome (0.1 mg/mL) and 100 µM TRZ in the presence of the NADPH-generating 
system for 5 min at 37ºC. The formation rate of 4-OH TRZ is expressed as a percentage relative to the 
activity in the absence of inhibitors. Data are shown as means of two determinations. 
 
 
 
 
Inhibitor concentration (µM) 
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Table 3. Reversible inhibition parameters (IC50) for 4-OH TRZ formation by CYP3A 
inhibitors in liver microsomes of humans, rats and mice 
 
 
IC50 (µM) 
Inhibitor 
Human Rat Mouse 
Erythromycin 76 775 1155 
Clarithromycin 143 448 1274 
Troleandomycin 46 131 35 
Diltiazem 62 24 19 
Nicardipine 0.4 0.7 1.7 
 
IC50 were calculated by nonlinear regression analysis using the data shown in Fig. 11. 
 
 
 
 
Relationship between kinact/KI ratios (MBI potency) and IC50 (reversible inhibition 
effect)  
 To examine the relationship between MBI potency and affinity for CYP3A of 
the five CYP3A inhibitors, the kinact/KI ratio was plotted against IC50. As shown in Fig. 
12, kinact/KI ratios were negatively correlated with IC50 (r = -0.820, p = 0.0003).  
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Fig. 12. Relationship between kinact/KI ratios (MBI potency) and IC50 (reversible 
inhibition) for CYP3A inhibitors.  
The kinact/KI ratio derived from MBI experiment was plotted against IC50 derived from reversible 
inhibition experiment. The relationship between kinact/KI ratio and IC50 was determined by linear 
regression analysis. Data of inhibition by erythromycin in rat liver microsomes were excluded from this 
plot, since the inactivation parameter for MBI could not be calculated because of weak inactivation effect. 
H, R and M represent data from humans, rats and mice, respectively. The correlation coefficient (r) and 
significant value (p) are also shown. 
 
 
II-I-IV: Discussion 
 In this study, we compared MBI potencies of CYP3A inhibitors for liver 
microsomes of humans, rats and mice using 4-OH TRZ formation as a marker of 
CYP3A activity. MBI potencies of CYP3A inhibitors exhibited species differences in 
humans, rats and mice that might be partly explained by different affinities of inhibitor 
for CYP3A. 
 Among the CYP3A inhibitors studied, erythromycin and clarithromycin 
showed marked differences in CYP3A inactivation according to species. Although 
erythromycin and clarithromycin remarkably produced time- and 
concentration-dependent inactivation of CYP3A in human liver microsomes, these 
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inactivation effects including MBI potencies in terms of kinact/KI ratios were much 
weaker in rat and mouse liver microsomes (Figs. 9A, 9B and Table 2). In addition, the 
results of spectroscopic experiments showed that erythromycin and clarithromycin 
cause spectral change characterized by a Soret peak with human liver microsomes but 
neither with rat nor mouse liver microsomes (Fig. 10). Taken together, these results 
suggest that erythromycin and clarithromycin cause significant MBI in human CYP3A 
but cause no or much weaker MBI in rat and mouse CYP3A. These species differences 
in CYP3A inactivation by erythromycin and clarithromycin in humans, rats and mice 
display species differences in CYP3A inactivation that might limit the use of rodents as 
in vivo models for prediction of MBI-mediated DDI.  
  In contrast to erythromycin and clarithromycin, time- and 
concentration-dependent inactivation effect on CYP3A activity of nicardipine in human 
liver microsomes were comparable to those in rat and mouse liver microsomes (Fig. 9E). 
Nicardipine showed a high kinact/KI ratio and nearly the same kinact in all species (Table 
2). In addition, the results of spectroscopic experiments showed that nicardipine formed 
a metabolic intermediate complex with rat and mouse liver microsomes (Figs. 10B and 
10C). These results suggest that there is negligible species differences in CYP3A 
inactivation by nicardipine. Although there has been no report on CYP3A inactivation 
by nicardipine in animals, nicardipine may be a common potent inactivator of CYP3A 
in humans, rats and mice. In the case of CYP3A inhibitors (e.g., nicardipine) for which 
MBI effects in humans are reproducible in animals in vitro, it may be possible to use 
animals as in vivo models for study of MBI-mediated DDI. 
  The time-dependent inactivation of CYP3A and formation of a metabolic 
intermediate complex by troleandomycin and diltiazem were also observed in rat and 
mouse liver microsomes (Figs. 9C, 9D, 10B and 10C), but some differences in the 
degree of inactivation among species were found (Table 2). Troleandomycin exhibited 
lower kinact and kinact/KI ratio in rat liver microsomes than in human and mouse liver 
microsomes, suggesting the potency of MBI by troleandomycin be smaller in rats than 
in humans and mice. Diltiazem showed lower kinact/KI ratio in rat liver microsomes than 
in human and mouse liver microsomes. However, diltiazem is not likely a weak 
inactivator in rat liver microsomes, since diltiazem showed high kinact. This discrepancy 
may be due to a higher KI in rat liver microsomes than in mouse or human liver 
microsomes.  
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To date, factors underlying species difference in CYP3A inactivation 
mediated by MBI are unknown. In the present study, we found that kinact/KI ratios (MBI 
potency) were negatively correlated with IC50 (reversible inhibition) (r = -0.820, p = 
0.0003) (Fig. 12). Since IC50 obtained from a reversible inhibition experiment is 
considered to reflect primarily affinity of the inhibitor for the enzyme [50,51], these 
results suggest that species differences in MBI potency may be partly explained by the 
different affinity for each CYP3A of the parent inhibitor. In humans, differential MBI of 
CYP3A4 and CYP3A5 has been reported [47,50,51]. CYP3A5 is less efficient in 
forming a metabolic intermediate complex than is CYP3A4. The smaller 
pharmacophore for CYP3A5 inhibition than that for CYP3A4 may possibly result in 
less energetic feasibility for inhibition by large-molecule inhibitors and less likelihood 
of secondary or tertiary metabolism [50,52]. The differences in pharmacophores for 
CYP3A4 and CYP3A5 inhibition may determine conformational states of the heme 
environment and accessibility of the nitroso group in the metabolic intermediate to the 
heme [51]. Although the pharmacophore for CYP3A inhibition in rodents has not been 
clarified, differences in amino acid sequences in human, rat and mouse CYP3A [53-55] 
would probably result in differences in pharmacophores for binding to inhibitors and 
metabolic intermediates among species. Although further studies on metabolism of 
parent inhibitors in each species and pharmacophores for CYP3A inhibition in rodents 
are needed, our results suggest that the different affinity for each CYP3A of the 
inhibitor may partly explain species differences of CYP3A inactivation mediated by 
MBI.  
In conclusion, the results of the present study suggest that there are species 
differences in MBI of CYP3A in humans, rats and mice. Although the factors 
underlying species differences in CYP3A inactivation remain to be clarified, affinity of 
the parent inhibitor for CYP3A may contribute to differences in MBI potency among 
species. Therefore, species differences in MBI of CYP3A should be considered when 
rodents are used as in vivo models for MBI-mediated DDI study.  
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II-II 
Mechanism-based inactivation effects of CYP3A inhibitors         
on CYP3A activity in CYP3As-humanized mice 
II-II-I: Introduction 
In Chapter II-I, we demonstrated that there were significant species 
differences in MBI potencies of some representative CYP3A inhibitors such as 
erythromycin and clarithromycin in humans, rats and mice. Our results suggest that the 
experimental animals especially rodents may be limited to use as in vivo models for 
study of clinical DDI induced by CYP3A inhibitors exhibiting species differences in 
MBI potencies in vitro. In this regard, it is thought that CYP3A-HAC mice may serve as 
useful models for prediction of clinical DDI induced by CYP3A-mediated MBI, since 
CYP3A-HAC mice possess the functional human CYP3A enzymes in the liver and 
intestine.  
 To assess whether CYP3A-HAC mice is useful for prediction of clinical DDI 
mediated by MBI of CYP3A, we performed in vitro studies on MBI effects on CYP3A 
acitivity of representative CYP3A inhibitors (erythromycin, clarithromycin, 
troleandomycin, diltiazem, verapamil, nicardipine, mifepristone and 
17α-ethinylestradiol [45-50,56,57]) in the liver and intestinal microsomes of 
CYP3A-HAC mice and compared with humans and WT mice.  
 
II-II-II: Materials and methods 
Chemicals  
 Mifepristone, verapamil, 17α-ethinylestradiol were purchased from Sigma-Aldrich. 
TRZ and 4’-OH TRZ were obtained from the same sources as detailed in Materials and 
Methods of Chapter I. Erythromycin, clarithromycin, troleandomycin, diltiazem and nicardipine 
were obtained from the same sources as detailed in Materials and Methods of Chapter II-I. 
Other reagents were of analytical or HPLC grade and obtained commercially. 
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HPLC analysis for 4-OH TRZ  
Determination of 4-OH TRZ was carried out using a Hitachi L-7000 model of HPLC 
system as described in Materials and Methods of Chapter I.  
Liver and intestinal microsomes 
 Pooled human liver microsomes prepared from 25-30 donors were purchased from 
BD gentest. Pooled human intestinal microsomes prepared from 18 donors were purchased from 
Xenotech. Pooled liver microsomes of WT mice (n = 8) and PCN-treated CYP3A-HAC mice (n 
= 4) and intestinal microsomes of WT mice (n = 8) and corn oil-treated CYP3A-HAC mice (n = 
3) were prepared as described in Materials and Methods of Chapter I.  
MBI effects of CYP3A inhibitors in liver microsomes 
 Liver microsomes of CYP3A-HAC mice, humans or WT mice (0.1 mg/mL) were 
preincubated at 37ºC with various concentrations of inhibitors in reaction mixtures each 
containing an NADPH-generating system in a final concentration of 250 µM. At various times, 
the stock of TRZ (2 µL of 25 mM TRZ in methanol) was added to preincubation mixture and 
incubated for another 10 min to measure the remaining catalytically active CYP3A. The 
reaction was terminated by addition of acetonitrile and the formation of 4-OH TRZ was 
determined by HPLC. Data were corrected for loss of activity in control incubation (no 
inhibitor) at each time point. All incubations were performed in three independent 
determinations.   
MBI effects of CYP3A inhibitors in intestinal microsomes 
 The assays of MBI in the intestinal microsomes were performed as described 
previously [39]. Briefly, the intestinal microsomes of humans, WT mice and CYP3A-HAC mice 
(0.5 mg/mL) were preincubated at 37°C with CYP3A inhibitors in reaction mixtures each 
containing 1 mM NADPH. After 0-min and 10-min incubation, aliquots of the preincubation 
mixture (25 µL) were diluted 10-fold with fresh reaction mixture containing 1 mM NADPH and 
400 µM TRZ to a final volume of 250 µL. The reactions were continued for 10 min and 
terminated by acetonitrile. Data were corrected for loss of activity in control incubation (no 
inhibitor) at each time. All incubations were performed in three independent determinations.  
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II-II-III: Results 
MBI effects of CYP3A inhibitors on CYP3A activity in the liver of CYP3A-HAC mice 
To assess whether CYP3A-HAC mice is useful for prediction of clinical DDI 
induced by CYP3A-mediated MBI, we investigated time-dependent inactivation effects 
of representative CYP3A inhibitors (erythromycin, clarithromycin, troleandomycin, 
diltiazem, verapamil, nicardipine, mifepristone and 17α-ethinylestradiol) on CYP3A 
activity in the liver microsomes of CYP3A-HAC mice comparing with humans and WT 
mice (Fig. 13). The formation of 4-OH TRZ was used as the marker of CYP3A activity. 
Among inhibitors studied, erythromycin and clarithromycin showed strong 
time-dependent inactivation effects on CYP3A activity in liver microsomes of 
CYP3A-HAC mice as well as in humans, but exhibited very weak time-dependent 
inactivation effects in liver microsomes of WT mice. Mifepristone showed 
time-dependent inactivation effect on CYP3A activity in all of liver microsomes of 
CYP3A-HAC mice, humans and WT mice, but its inactivation effect was much stronger 
in liver microsomes of CYP3A-HAC mice and humans than in WT mice. In contrast, 
diltiazem, verapamil and 17α-ethinylestradiol showed weaker time-dependent 
inactivation effects on CYP3A activity in liver microsomes of CYP3A-HAC mice and 
humans than in WT mice. Troleandomycin and nicardipine exhibited almost similar 
time-dependent inactivation effects on CYP3A activity in liver microsomes of 
CYP3A-HAC mice, humans and WT mice.  
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Fig. 13. Time-dependent inhibition of 4-OH TRZ formation by CYP3A inhibitors 
in the liver microsomes of CYP3A-HAC mice, humans and WT mice. 
After preincubation of CYP3A inhibitors with liver microsomes of CYP3A-HAC mice (close circles), 
humans (open triangles) or WT mice (open squares) at several times in the presence of an 
NADPH-generating system at 37ºC, TRZ was added to determine the remaining activity of CYP3A. 
Incubation was continued for 10 min at 37ºC. The CYP3A inhibitors used were (A) 50 µM erythromycin, 
(B) 50 µM clarithromycin, (C) 1 µM mifepristone, (D) 10 µM diltiazem, (E) 2 µM verapamil, (F) 20 µM 
17α-ethinylestradiol, (G) 10 µM troleandomycin and (H) 1 µM nicardipine. Data are shown as means 
of % remaining activity ± S.D. from three determinations relative to the activity in the absence of 
inhibitors at each time. 
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MBI effects of CYP3A inhibitors on CYP3A activity in the intestines of CYP3A-HAC 
mice 
Since erythromycin and clarithromycin showed very weak MBI effects on 
CYP3A activity in the liver of WT mice, we selected erythromycin and clarithromycin 
as CYP3A inhibitors for the investigation of MBI effects on CYP3A activity in the 
intestinal microsomes of CYP3A-HAC mice, comparing with humans and WT mice. As 
shown in Fig. 14, erythromycin and clarithromycin inhibited the formation of 4-OH 
TRZ after 10-min preincubation with intestinal microsomes of CYP3A-HAC mice and 
humans, but not inhibited the formation of 4-OH TRZ in intestinal microsomes of WT 
mice. 
 
 
 (A) Erythromycin                  (B) Clarithromycin 
 
 
 
 
 
 
 
 
 
Fig. 14. Time-dependent inhibition of 4-OH TRZ formation by erythromycin (A) 
and clarithromycin (B) in the intestinal microsomes of CYP3A-HAC mice, humans 
and WT mice.  
Intestinal microsomes of CYP3A-HAC mice, WT mice or humans were preincubated with erythromycin 
(100 µM) or clarithromycin (100 µM) in the presence of 1 mM NADPH for 0 or 10 min at 37ºC. The 
preincubation mixture was then diluted 10-fold with the fresh incubation mixture containing TRZ (400 
µM) and 1mM NADPH and incubated for another 10 min to determine the remaining of CYP3A activity. 
Data are shown as means of % remaining activity ± S.D. from three determinations relative to the activity 
in the absence of inhibitors at each time point. 
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II-II-IV: Discussion 
 Experimental animals are not always reliable as the in vivo models for 
prediction of clinical DDI potential induced by CYP3A-mediated MBI, since there are 
significant species differences in MBI of CYP3A between humans and experimental 
animals as described in the part I of this chapter. In this study, we demonstrated that 
MBI effects of representative inhibitors on CYP3A activity in CYP3A-HAC mice were 
comparable with humans in both the liver and intestine, suggesting the possibility to use 
CYP3A-HAC mouse line as in vivo animal model for prediction of clinical DDI 
mediated by MBI of CYP3A. 
 Although using human liver and intestinal microsomes, hepatocytes and 
cDNA-expressed enzymes has been successful for evaluation of MBI potential of drug 
candidates in vitro [4,41,42], they cannot be appropriately indicative for prediction of 
clinical DDI potential in vivo. This is because the results obtained from the in vitro 
studies cannot correctly predict the clinical DDI caused by the inactivation of CYP3A 
from the multiple dosing of drugs. In addition, they cannot predict how long the clinical 
DDI mediated by irreversible inhibition will last after discontinuation of CYP3A 
inhibitors. Although rodents have been generally used as in vivo animal models in the 
preclinical study of new drug development, using rodents might be limited in the 
predicting clinical DDI induced by MBI of CYP3A because of significant species 
differences in MBI potencies of CYP3A inhibitors as shown in this study. Up to date, 
there is only one report showing that MBI-mediated DDI induced by the clinical dose of 
mibefradil could be reproduced in rats in vivo [7]. Although some researchers have tried 
to use rats as in vivo models for prediction of MBI-mediated DDI by erythromycin as a 
typical CYP3A inhibitor, no one could demonstrate that erythromycin caused 
MBI-mediated DDI in rats treated in the clinical doses [58,59]. In contrast to rodents, 
there are similarities in functional activities and amino acid sequences of CYP3A 
between monkeys and humans [60,61]. Recently, it has been reported that MBI-induced 
DDI in humans by erythromycin, clarithromycin and azithromycin could be reproduced 
in cynomolgus monkeys treated in the clinical doses [62]. Although these findings 
suggest that monkeys are useful as in vivo animal models for prediction of human DDI 
induced by CYP3A-mediated MBI, it is not guaranteed that monkeys can be the suitable 
models for prediction the clinical DDI induced by all drug candidates because they are 
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not carry the human CYP3A. 
 Since the human CYP3A enzymes are expressed in both liver and intestine of 
CYP3A-HAC mouse line, it has been considered that CYP3A-HAC mice may be the 
useful in vivo models for prediction of clinical DDI potential induced by MBI of 
CYP3A in the whole body. In the present study, we demonstrated that erythromycin, 
clarithromycin, mifepristone, diltiazem, verapamil and 17α-ethinylestradiol exhibited 
species differences in MBI effects on CYP3A activity between humans and mice in 
vitro, but their MBI effects on CYP3A activity in humans were comparable with 
CYP3A-HAC mice in both liver and intestine (Figs. 13 and 14). These results suggest 
that CYP3A-HAC mice would be useful as in vivo animal models for prediction of 
clinical DDI induced by MBI of CYP3A, especially for drugs exhibiting species 
differences in MBI effects on CYP3A activity. CYP3A-HAC mouse line would also be 
useful for time-course study of inactivation effect on CYP3A activity of the different 
dosage regimens and time-course study on the recovery of CYP3A activity after 
discontinuation of CYP3A inhibitors. 
 Among CYP3A inhibitors, some drugs also act as inducers of CYP3A. For 
example, after administration repeated doses of troleandomycin in humans, 
troleandomycin induced the expression of CYP3A enzymes and promoted its own 
transformation into an active metabolite with forming an inactive complex with CYP3A 
[48]. Therefore, further in vivo studies are needed to investigate overall effects of 
inhibition and induction of drug candidates on CYP3A activity. The induction of 
CYP3A expression is mainly regulated by nuclear receptor PXR, but PXR showed 
species differences in ligand responses [34]. Thus, WT animals would be inadequate to 
predict the clinical DDI potential mediated by CYP3A induction for some drug 
candidates. Since the present CYP3A-HAC mouse line carries mouse PXR but not 
human PXR, the development of CYP3A-HAC mouse line carrying human PXR would 
yield more reliable in vivo model for prediction of clinical DDI mediated by overall 
inhibition and induction effect of drug candidates on CYP3A activity. 
 In conclusion, the results of in vitro inhibition studies showed that MBI 
effects of the representative CYP3A inhibitors on CYP3A activity in the liver and 
intestinal microsomes of CYP3A-HAC mice were comparable to those in human 
samples, but were different from those in WT mice samples. Although further in vivo 
DDI study is needed to confirm the usefulness of CYP3A-HAC, our results suggest that 
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CYP3A-HAC mouse line would be useful in vivo model for prediction of clinical DDI 
potential induced by MBI of CYP3A.  
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Conclusions 
In the present study, we performed the functional characterization of 
CYP3A-HAC mice, assessed whether CYP3A-HAC mice is useful for prediction of 
clinical DDI potential induced by CYP3A-mediated MBI, and obtained the following 
results: 
 
1. CYP3A4 mRNA and CYP3A proteins were expressed in both the liver and intestine 
of CYP3A HAC mice.  
2. The functional CYP3A enzymes were expressed in both the liver and intestine of 
CYP3A-HAC mice, which could be induced by the treatment with PCN, a typical 
CYP3A inducer.  
3. In CYP3A-KO mice, the expression and metabolic activity of CYP3A were 
negligible in liver and intestine and no induction effect of PCN was found. 
4. The kinetic profiles of TRZ metabolism in the liver and intestine of CYP3A-HAC 
mice were comparable to those in humans, but were different from those in WT mice.  
5. The anti-human CYP3A4 antibody could inhibit CYP3A activity in the liver and 
intestine of CYP3A-HAC mice, but could not inhibit CYP3A activity in those of WT 
mice. 
6. Species differences in MBI of CYP3A were found in humans, rats and mice, which 
should be considered when rodents are used as models for MBI-mediated DDI study.  
7. The MBI effects of representative CYP3A inhibitors on CYP3A activity in both the 
liver and intestine of CYP3A-HAC mice were well comparable to those in humans, 
but were different from those in WT mice.  
 
Taken together, our results suggest that CYP3A-HAC mouse line would be 
the useful in vivo model for prediction of human pharmacokinetics including clinical 
DDI potential mediated by MBI of CYP3A, although further in vivo studies are 
needed to confirm the usefulness of CYP3A-HAC mouse line.  
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Appendix 1. Protein concentrations of microsomes and incubation times used for 
determination of TRZ-hydroxylase activity in Chapter I 
Sample Protein concentration (mg/mL) Incubation time (min) 
Liver microsome   
  WT/oil 0.05 20 
  WT/PCN 0.05 20 
  CYP3A-KO/oil 0.15 30 
  CYP3A-KO/PCN 0.15 30 
  CYP3A-HAC/oil 0.15 30 
  CYP3A-HAC/PCN 0.15 30 
  Human 0.01 30 
   
Intestinal microsome   
  WT/oil 0.25 30 
  WT/PCN 0.25 30 
  CYP3A-KO/oil 0.25 30 
  CYP3A-KO/PCN 0.25 30 
  CYP3A-HAC/oil 0.25 30 
  CYP3A-HAC/PCN 0.25 30 
  Human 0.25 30 
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